Pegcrisantaspase

Acute Myeloid Leukemia

M.D. Anderson Cancer CenterPhase 1Dormant

C

32/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 17/ 100
Competitive Position: 89/ 100

Competitive context

685 Active assets in the Acute Myeloid Leukemia cohort.

Asset / Sponsor	Phase	Rating
Gemtuzumab M.D. Anderson Cancer Center	Phase 4	A
AMSACRINE University Hospital, Toulouse	Phase 4	BBB
Posaconazole AstraZeneca	Phase 4	BBB
(+)-VINCRISTINE Janssen Research & Development, LLC	Phase 3	BBB
AKLAVINE Chinese PLA General Hospital	Phase 4	BB

View all 50 →

Same molecule, other indications

Pegcrisantaspase is also rated in:

acute lymphoblastic leukemiaDormant

CC

Indicative ·

40 / 100

lymphoblastic lymphomaDormant

C

Indicative ·

36 / 100

blast phase chronic myelogenous leukemia, BCR-ABL1 positiveDormant

D

Indicative ·

30 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.